vs
Enact Holdings, Inc.（ACT）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Guardant Health, Inc.的1.1倍（$312.1M vs $281.3M），Enact Holdings, Inc.净利率更高（53.8% vs -45.7%，领先99.5%），Guardant Health, Inc.同比增速更快（39.4% vs 1.7%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 2.2%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
ACT vs GH — 直观对比
营收规模更大
ACT
是对方的1.1倍
$281.3M
营收增速更快
GH
高出37.6%
1.7%
净利率更高
ACT
高出99.5%
-45.7%
两年增速更快
GH
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.1M | $281.3M |
| 净利润 | $168.0M | $-128.5M |
| 毛利率 | — | 64.6% |
| 营业利润率 | — | -43.0% |
| 净利率 | 53.8% | -45.7% |
| 营收同比 | 1.7% | 39.4% |
| 净利润同比 | 1.2% | -15.8% |
| 每股收益（稀释后） | $1.18 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTGH
| Q1 26 | $312.1M | — | ||
| Q4 25 | $312.7M | $281.3M | ||
| Q3 25 | $311.5M | $265.2M | ||
| Q2 25 | $304.9M | $232.1M | ||
| Q1 25 | $306.8M | $203.5M | ||
| Q4 24 | $301.8M | $201.8M | ||
| Q3 24 | $309.6M | $191.5M | ||
| Q2 24 | $298.8M | $177.2M |
净利润ACTGH
| Q1 26 | $168.0M | — | ||
| Q4 25 | — | $-128.5M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | — | $-107.8M | ||
| Q2 24 | — | $-102.6M |
毛利率ACTGH
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% |
营业利润率ACTGH
| Q1 26 | — | — | ||
| Q4 25 | 71.3% | -43.0% | ||
| Q3 25 | 67.4% | -37.3% | ||
| Q2 25 | 70.4% | -45.9% | ||
| Q1 25 | 68.9% | -54.6% | ||
| Q4 24 | 68.9% | -62.4% | ||
| Q3 24 | 74.1% | -61.3% | ||
| Q2 24 | 78.6% | -56.8% |
净利率ACTGH
| Q1 26 | 53.8% | — | ||
| Q4 25 | — | -45.7% | ||
| Q3 25 | — | -35.0% | ||
| Q2 25 | — | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | — | -56.3% | ||
| Q2 24 | — | -57.9% |
每股收益（稀释后）ACTGH
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.23 | $-1.01 | ||
| Q3 25 | $1.10 | $-0.74 | ||
| Q2 25 | $1.11 | $-0.80 | ||
| Q1 25 | $1.08 | $-0.77 | ||
| Q4 24 | $1.05 | $-0.90 | ||
| Q3 24 | $1.15 | $-0.88 | ||
| Q2 24 | $1.16 | $-0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $549.0M | $378.2M |
| 总债务越低越好 | $744.9M | $1.5B |
| 股东权益账面价值 | $5.3B | $-99.3M |
| 总资产 | $7.0B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTGH
| Q1 26 | $549.0M | — | ||
| Q4 25 | $582.5M | $378.2M | ||
| Q3 25 | $545.6M | $580.0M | ||
| Q2 25 | $616.0M | $629.1M | ||
| Q1 25 | $639.0M | $698.6M | ||
| Q4 24 | $602.8M | $525.5M | ||
| Q3 24 | $674.9M | $585.0M | ||
| Q2 24 | $711.3M | $933.7M |
总债务ACTGH
| Q1 26 | $744.9M | — | ||
| Q4 25 | $744.5M | $1.5B | ||
| Q3 25 | $744.1M | $1.1B | ||
| Q2 25 | $743.8M | $1.1B | ||
| Q1 25 | $743.4M | $1.1B | ||
| Q4 24 | $743.0M | $1.1B | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — |
股东权益ACTGH
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.4B | $-99.3M | ||
| Q3 25 | $5.3B | $-354.5M | ||
| Q2 25 | $5.2B | $-305.5M | ||
| Q1 25 | $5.1B | $-250.8M | ||
| Q4 24 | $5.0B | $-139.6M | ||
| Q3 24 | $5.0B | $-60.1M | ||
| Q2 24 | $4.8B | $-1.6M |
总资产ACTGH
| Q1 26 | $7.0B | — | ||
| Q4 25 | $6.9B | $2.0B | ||
| Q3 25 | $6.9B | $1.3B | ||
| Q2 25 | $6.8B | $1.3B | ||
| Q1 25 | $6.7B | $1.3B | ||
| Q4 24 | $6.5B | $1.5B | ||
| Q3 24 | $6.6B | $1.5B | ||
| Q2 24 | $6.3B | $1.6B |
负债/权益比ACTGH
| Q1 26 | 0.14× | — | ||
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-54.2M |
| 自由现金流率自由现金流/营收 | — | -19.3% |
| 资本支出强度资本支出/营收 | — | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流ACTGH
| Q1 26 | — | — | ||
| Q4 25 | $724.5M | $-26.4M | ||
| Q3 25 | $192.0M | $-35.4M | ||
| Q2 25 | $119.5M | $-60.3M | ||
| Q1 25 | $226.7M | $-62.7M | ||
| Q4 24 | $686.3M | $-64.5M | ||
| Q3 24 | $188.1M | $-51.1M | ||
| Q2 24 | $144.7M | $-94.0M |
自由现金流ACTGH
| Q1 26 | — | — | ||
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M |
自由现金流率ACTGH
| Q1 26 | — | — | ||
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% |
资本支出强度ACTGH
| Q1 26 | — | — | ||
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
| Premiums | $242.8M | 78% |
| Other | $69.2M | 22% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
